{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:55:16Z","timestamp":1794002116594,"version":"4.8.0"},"reference-count":33,"publisher":"Informa UK Limited","issue":"18","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2026,7,27]]},"DOI":"10.1080\/14796694.2026.2701483","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T13:14:24Z","timestamp":1785503664000},"page":"2121-2129","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS\u2009&lt;10"],"prefix":"10.1080","volume":"22","author":[{"given":"Hope S.","family":"Rugo","sequence":"first","affiliation":[{"name":"City of Hope Comprehensive Cancer Center","place":["Duarte, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schmid","sequence":"additional","affiliation":[{"name":"Queen Mary University of London","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7623-1583","authenticated-orcid":false,"given":"Javier","family":"Cortes","sequence":"additional","affiliation":[{"name":"Quiron Group","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimi","family":"Takano","sequence":"additional","affiliation":[{"name":"Cancer Institute Hospital of Japanese Foundation for Cancer Research","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Fasching","sequence":"additional","affiliation":[{"name":"University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg","place":["Erlangen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon Hee","family":"Park","sequence":"additional","affiliation":[{"name":"Sungkyunkwan University School of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6790-6267","authenticated-orcid":false,"given":"Giampaolo","family":"Bianchini","sequence":"additional","affiliation":[{"name":"IRCCS Ospedale","place":["San Raffaele, Milan, Italy"]},{"name":"Vita-Salute San Raffaele University","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra Ximena","family":"Franco","sequence":"additional","affiliation":[{"name":"Centro de Tratamiento e Investigaci\u00f3n sobre C\u00e1ncer Luis Carlos Sarmiento Angulo","place":["Bogota, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Villarreal-Garza","sequence":"additional","affiliation":[{"name":"Breast Cancer Center Hospital Zambrano Hellion TecSalud","place":["San Pedro Garza Garc\u00eda, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Tredan","sequence":"additional","affiliation":[{"name":"Centre L\u00e9on B\u00e9rard and Cancer Research Center of Lyon","place":["Lyon, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Yin","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romualdo","family":"Barroso-Sousa","sequence":"additional","affiliation":[{"name":"Brasilia Hospital","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Peng","sequence":"additional","affiliation":[{"name":"Inc","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha","family":"Malhotra","sequence":"additional","affiliation":[{"name":"Inc","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Lisa","family":"Smith","sequence":"additional","affiliation":[{"name":"Inc","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Bardia","sequence":"additional","affiliation":[{"name":"University of California Los Angeles, Jonsson Comprehensive Cancer Center","place":["Los Angeles, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"e_1_3_7_3_1","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast cancer. Version 4. 2025 Available from: https:\/\/www.nccn.org\/"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1001389"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22836"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27581"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-3045"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-481154"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.019"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/11782234231203292"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1021"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf034"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25615"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.18632\/genesandcancer.40"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235936"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10076-7"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep33658"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.104"},{"key":"e_1_3_7_20_1","unstructured":"Kelun-Biotech Biopharmaceutical S. Kelun-Biotech\u2019s TROP2 ADC sacituzumab tirumotecan (sac-TMT \u4f73\u6cf0\u83b1) approved for marketing by NMPA of China for 2L+ advanced or metastatic TNBC. 2024. Available from: https:\/\/www.kluspharma.com\/news\/kelun-biotech%E2%80%99s-trop2-adc-sacituzumab-tirumotecan-(sac-tmt%2C-%E4%BD%B3%E6%B3%B0%E8%8E%B1%C2%AE)-approved-for-marketing-by-nmpa-of-china-for-2l%2B-advanced-or-metastatic-tnbc"},{"issue":"17","key":"e_1_3_7_21_1","first-page":"LBA109","article-title":"Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1\u2013positive advanced triple-negative breast cancer (TNBC): primary results from the randomized phase 3 ASCENT-04\/KEYNOTE-D19 study","volume":"43","author":"Tolaney SM","year":"2025","unstructured":"Tolaney SM, Ed A, Kalinsky K, et al. Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1\u2013positive advanced triple-negative breast cancer (TNBC): primary results from the randomized phase 3 ASCENT-04\/KEYNOTE-D19 study. J Clin Oncol. 2025;43(suppl 17):LBA109.","journal-title":"J Clin Oncol"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511734"},{"key":"e_1_3_7_23_1","volume-title":"LBA21 - first-line (1L) datopotamab deruxtecan (dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: primary results from the randomised, phase III TROPION-Breast02 trial","author":"Dent RA","year":"2025","unstructured":"Dent RA, Shao Z, Schmid P, et al., editors. LBA21 - first-line (1L) datopotamab deruxtecan (dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: primary results from the randomised, phase III TROPION-Breast02 trial. Berlin, Germany: European Society for Medical Oncology (ESMO); 2025."},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102395"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01509-2"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-014-0111-4"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2026.05.693"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103203"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.9004"},{"issue":"2","key":"e_1_3_7_30_1","first-page":"S1315","article-title":"2421P - Sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) in metastatic castration-resistant prostate cancer (mCRPC): results from phase II MK-2870\u2013002\/SKB264-II-06 study","volume":"36","author":"Bian X","year":"2025","unstructured":"Bian X, Jiang S, Goh JC, et al. 2421P - Sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) in metastatic castration-resistant prostate cancer (mCRPC): results from phase II MK-2870\u2013002\/SKB264-II-06 study. Ann Oncol. 2025;36(Suppl 2):S1315.","journal-title":"Ann Oncol"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.951589"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.8529"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03630-w"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.1019"},{"key":"e_1_3_7_35_1","volume-title":"LBA23 - sacituzumab tirumotecan (sac-TMT) vs investigator\u2019s choice of chemotherapy (ICC) in previously treated locally advanced or metastatic hormone receptor-positive, HER2-negative (HR+\/HER2-) breast cancer (BC): results from the randomized, multi-center phase III OptiTROP-Breast02 study","author":"Li M","year":"2025","unstructured":"Li M, Fan Y, Li H, et al., editors. LBA23 - sacituzumab tirumotecan (sac-TMT) vs investigator\u2019s choice of chemotherapy (ICC) in previously treated locally advanced or metastatic hormone receptor-positive, HER2-negative (HR+\/HER2-) breast cancer (BC): results from the randomized, multi-center phase III OptiTROP-Breast02 study. Berlin, Germany: European Society for Medical Oncology (ESMO); 2025."}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2026.2701483","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14796694.2026.2701483","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2026.2701483","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T08:12:53Z","timestamp":1785917573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2026.2701483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":33,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2026,7,27]]}},"alternative-id":["10.1080\/14796694.2026.2701483"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2026.2701483","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-03-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}